Replies to post #90771 on Biotech Values

[DewDiligence]

Regardless of how this works out, someone at ITMN is getting plaudits for having ensured that ITMN collects milestones and royalties from Roche for any HCV PI that Roche decides to develop.

[DewDiligence]

I took the “may” more in reference to study initiation timeline.

I respectfully disagree on this consequential point of interpretation. If the word “may” was meant to qualify only the timing of the trial start—rather than the question of whether the trial will start at all—why didn’t the language in ITMN’s PR say:

“The study is expected to start in late 2010 or early 2011.” ?

That would have been crystal clear, and I surmise that Roche chose a different wording because they wanted to avoid such clarity.